|
1
|
Lin Y, Peng S, Yu H, Teng H and Cui M:
RNAi-mediated downregulation of NOB1 suppresses the growth and
colony-formation ability of human ovarian cancer cells. Med Oncol.
29:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Auersperg N, Wong AS, Choi KC, Kang SK and
Leung PC: Ovarian surface epithelium: biology, endocrinology, and
pathology. Endocr Rev. 22:255–258. 2001.PubMed/NCBI
|
|
3
|
Ziebarth AJ, Landen CN Jr and Alvarez RD:
Molecular/genetic therapies in ovarian cancer: future opportunities
and challenges. Clin Obstet Gynecol. 55:156–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang H, Linghu H, Wang J, Che YL, Xiang
TX, Tang WX and Yao ZW: The role of Crk/Dock180/Rac1 pathway in the
malignant behavior of human ovarian cancer cell SKOV3. Tumour Biol.
31:59–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fader AN and Rose PG: Role of surgery in
ovarian carcinoma. J Clin Oncol. 25:2873–2883. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salzberg M, Thurlimann B, Bonnefois H,
Fink D, Rochlitz C, Von Moos R and Senn H: Current concepts of
treatment strategies in advanced or recurrent ovarian cancer.
Oncology. 68:293–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McGuire WP and Ozols RF: Chemotherapy of
advanced ovarian cancer. Semin Oncol. 25:340–348. 1998.PubMed/NCBI
|
|
8
|
Fung-Kee-Fung M, Oliver T, Elit L, Oza A,
Hirte HW and Bryson P: Optimal chemotherapy treatment for women
with recurrent ovarian cancer. Curr Oncol. 14:195–208. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dempke W, Rie C, Grothey A and Schmoll HJ:
Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer
Res Clin Oncol. 127:411–417. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li S, Miner K, Fannin R, Carl Barrett J
and Davis BJ: Cyclooxygenase-1 and 2 in normal and malignant human
ovarian epithelium. Gynecol Oncol. 92:622–627. 2004. View Article : Google Scholar
|
|
12
|
Denkert C, Köbel M, Pest S, Koch I, Berger
S, Schwabe M, Siegert A, Reles A, Klosterhalfen B and Hauptmann S:
Expression of cyclooxygenase-2 is an independent prognostic factor
in human ovarian carcinoma. Am J Pathol. 160:893–903. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Erkinheimo TL, Lassus H, Finne P, van Rees
BP, Leminen A, Ylikorkala O, Haglund C, Butzow R and Ristimäki A:
Elevated cyclooxygenase-2 expression is associated with altered
expression of p53 and SMAD4, amplification of HER-2/neu, and poor
outcome in serous ovarian carcinoma. Clin Cancer Res. 10:538–545.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arico S, Pattingre S, Bauvy C, Gane P,
Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis
by inhibiting 3-phosphoinositide-dependent protein kinase-1
activity in the human colon cancer HT-29 cell line. J Biol Chem.
277:27613–27621. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cerutti H: RNA interference: traveling in
the cell and gaining functions? Trends Genet. 19:39–46. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature.
391:806–811. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hannon GL and Rossi JJ: Unlocking the
potential of the human genome with RNA interference. Nature.
431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Izquierdo M: Short interfering RNAs as a
tool for cancer gene therapy. Cancer Gene Ther. 12:217–227. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Caplen NJ: Gene therapy progress and
prospects. Downregulating gene expression: the impact of RNA
interference. Gene Ther. 11:1241–1248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elbashir SM, Harborth J, Weber K and
Tuschl T: Analysis of gene function in somatic mammalian cells
using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tai MH, Weng CH, Mon DP, Hu CY and Wu MH:
Ultraviolet C irradiation induces different expression of
cyclooxygenase 2 in NIH 3T3 cells and A431 cells: the roles of
COX-2 are different in various cell lines. Int J Mol Sci.
13:4351–4366. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim DH, Longo M, Han Y, Lundberg P, Cantin
E and Rossi JJ: Interferon induction by siRNAs and ssRNAs
synthesized by phage polymerase. Nat Biotechnol. 22:321–325. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meister G and Tuschi T: Mechanisms of gene
silencing by double-stranded RNA. Nature. 431:343–349. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mello CC and Conte D Jr: Revealing the
world of RNA interference. Nature. 431:338–342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang R, Wang X, Lin F, Gao P, Dong K and
Zhang HZ: shRNA-targeted cyclooxygenase (COX)-2 inhibits
proliferation, reduces invasion and enhances chemosensitivity in
laryngeal carcinoma cells. Mol Cell Biochem. 317:179–188. 2008.
View Article : Google Scholar
|
|
27
|
Chen Q, Pan Q, Cai R and Qian C: Prospects
of RNA interference induced by RNA Pol II promoter in cancer
therapy. Prog Biochem Biophys. 34:806–815. 2007.
|
|
28
|
Strillacci A, Griffoni C, Spisni E, Manara
MC and Tomasi V: RNA interference as a key to knockdown
overexpressed cyclooxygenase-2 gene in tumour cells. Br J Cancer.
94:1300–1310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vogler M, Walczak H, Stadel D, Haas TL,
Genze F, Jovanovic M, Gschwend JE, Simmet T, Debatin KM and Fulda
S: Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and
cooperates with TRAIL to suppress pancreatic cancer growth in vitro
and in vivo. Cancer Res. 68:7956–7965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM
and Zhang ST: Effects of cyclooxygenase-2 on human esophageal
squamous cell carcinoma. World J Gastroenterol. 17:4572–4580. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Denkert C, Fürstenberg A, Daniel PT, Koch
I, Köbel M, Weichert W, Siegert A and Hauptmann S: Induction of
G0/G1 cell cycle arrest in ovarian carcinoma cells by the
anti-inflammatory drug NS-398, but not by COX-2-specific RNA
interference. Oncogene. 22:8653–8661. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park W, Oh YT, Han JH and Pyo H: Antitumor
enhancement of celecoxib, a selective cyclooxygenase-2 inhibitor,
in a Lewis lung carcinoma expressing cyclooxygenase-2. J Exp Clin
Cancer Res. 27:662008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Müller-Decker K and Fürstenberger G: The
cyclooxygenase-2-mediated prostaglandin signaling is causally
related to epithelial carcinogenesis. Mol Carcinog. 46:705–710.
2007.PubMed/NCBI
|
|
34
|
Leahy KM, Ornberg RL, Wang Y, Zweifel BS,
Koki AT and Masferrer JL: Cyclooxygenase-2 inhibition by celecoxib
reduces proliferation and induces apoptosis in angiogenic
endothelial cells in vivo. Cancer Res. 62:625–631. 2002.PubMed/NCBI
|
|
35
|
Mamdani M, Juurlink DN, Lee DS, Rochon PA,
Koop A, Naglie G, Austin PC, Laupacis A and Stukel TA:
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal
anti-inflammatory drugs and congestive heart failure outcomes in
elderly patients: a population-based cohort study. Lancet.
363:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rasmuson A, Kock A, Fuskevåg OM, Kruspig
B, Simón-Santamaría J, Gogvadze V, Johnsen JI, Kogner P and
Sveinbjörnsson B: Autocrine prostaglandin E2 signaling promotes
tumor cell survival and proliferation in childhood neuroblastoma.
PLoS One. 7:e293312012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pockaj BA, Basu GD, Pathangey LB, Gray RJ,
Hernandez JL, Gendler SJ and Mukherjee P: Reduced T-cell and
dendritic cell function is related to cyclooxygenase-2
overexpression and prostaglandin E2 secretion in patients with
breast cancer. Ann Surg Oncol. 11:328–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iñiguez MA, Rodríguez A, Volpert OV,
Fresno M and Redondo JM: Cyclooxygenase-2: a therapeutic target in
angiogenesis. Trends Mol Med. 9:73–78. 2003.
|
